

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-133) ELUVIXTAMAB  
PRONUNCIATION el" ue vix' ta mab  
THERAPEUTIC CLAIM Treatment of acute myeloid leukemia (AML)

## CHEMICAL NAMES

1. Immunoglobulin, anti-(human sialic acid-binding Ig-like lectin 3) (human monoclonal 1803MNGssmAbc single-chain variable fragment VH1-(GGGGS)3-VL1) fusion protein with peptide linker (GGGGS) fusion protein with Immunoglobulin anti-(human CD3 antigen  $\epsilon$ -chain) (human monoclonal 1803MNGssmAbc single-chain variable fragment VH2-(GGGGS)3-VL2) (Source: CAS)
2. Immunoglobulin scFv-scFv, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)] and anti-[*Homo sapiens* CD3E (CD3 epsilon)], monoclonal antibody single chain, bispecific; IG scFv-scFv single chain, anti-CD33 and anti-CD3E (1-511) [scFv-VH-V-kappa anti-CD33 (1-250) [VH (*Homo sapiens*IGHV1-18\*01 (82.7%) -(IGHD) -IGHJ4\*01 (93.3%)) CDR-IMGT [8.8.15] (26-33.51-58.97-111) (1-122)-15-mer tris(tetraglycyl-seryl) linker (123-137) -V-KAPPA (*Homo sapiens*IGKV4-1\*01 (83.2%) -IGKJ5\*01 (100%)) CDR-IMGT [12.3.9] (164-175.193-195.232-240) (138-250)] -6-mer seryl-tetraglycyl-seryl linker (251-256) -scFv-VH-V-lambda anti-CD3E (257-505) [VH (*Mus musculus*IGHV10-1\*02 (91.9%) -(IGHD)-IGHJ3\*01 (86.7%)/*Homo sapiens*IGHV3-73\*01 (87%) -(IGHD) -IGHJ5\*01 (100%)) CDR-IMGT [8.10.16] (282-289.307-316.355-370) (257-381) -15-mer tris(tetraglycyl-seryl) linker (382-396) -V-LAMBDA (*Homo sapiens*IGLV7-43\*01 (85.1%) -IGLJ3\*02 (100%)) CDR-IMGT [9.3.9] (422-430.448-450.487-495) (397-505)] -hexahistidine (506-511)], produced in Chinese hamster ovary (CHO) cells, non-glycosylated (Source: WHO pINN list 123)

## STRUCTURAL FORMULA

Sequence

|            |             |            |             |            |     |
|------------|-------------|------------|-------------|------------|-----|
| QVQLVQSGAE | VKKPGESVKV  | SCKASGYTFT | NYGMNWVKQA  | PGQGLEWMGW | 50  |
| INTYTGPTY  | ADKFQGRVTM  | TTDTSTSTAY | MEIRNLGGDD  | TAVYYCARWS | 100 |
| WSDGYVYFD  | YWGQGTSTVTV | SSGGGSGGG  | GSGGGSDIV   | MTQSPDSLTV | 150 |
| SLGERTTINC | KSSQSVLDSS  | TNKNLAWYQ  | QKPGQPPKLL  | LSWASTRESG | 200 |
| IPDRFSGSGS | GTDFTLTIDS  | PQPEDSATYY | CQQSAHFPIIT | FGQGRLEIK  | 250 |
| SGGGGSEVQL | VESGGGLVQP  | GGSLKLSCAA | SGFTFNKYAM  | NWVRQAPGKG | 300 |
| LEWVARIRSK | YNNYATYYAD  | SVKDRFTISR | DDSKNTAYLQ  | MNNLKTEDTA | 350 |
| VYICVRHGNF | GNSYISYWAY  | WGQGTLVTVS | SGGGGSGGG   | SGGGGQTVV  | 400 |
| TQEPSLTVSP | GGTVTLTCGS  | STGAVTSGNY | PNWVQKPGQ   | APRGLIGGTK | 450 |
| FLAPGTPARF | SGSLLGGKAA  | LTLSGVQPED | EAEYCVLWY   | SNRWVFGGTT | 500 |
| KLTVLHHHHH | H           |            |             |            | 511 |

### Disulfide bridges

22-96 160-231 278-354 418-486

|                            |   |
|----------------------------|---|
| MOLECULAR FORMULA          | C <sub>2396</sub> H <sub>3620</sub> N <sub>658</sub> O <sub>764</sub> S <sub>15</sub> |
| MOLECULAR WEIGHT           | 54.3 kDa  |
| TRADEMARK                  | None as yet   |
| SPONSOR                    | Amgen   |
| CODE DESIGNATIONS          | AMG330  |
| <u>CAS</u> REGISTRY NUMBER | 1679391-73-1  |
| UNII                       | 6Z4B5PJ4OP  |
| WHO NUMBER                 | 11240   |

gbk